Navidea biopharmaceuticals announces launch of phase 3 clinical trial in rheumatoid arthritis

Dublin, ohio--(business wire)--navidea biopharmaceuticals, inc. (nyse american: navb) (“navidea” or the “company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the launch of the nav3-33 phase 3 clinical trial titled “evaluation of tc99m tilmanocept imaging for the early prediction of anti-tnfΑ therapy response in patients with moderate to severe active rheumatoid arthritis (ra).” this phase 3 trial will establish the ability
NAVB Ratings Summary
NAVB Quant Ranking